Unleash Immuno Oncolytics is an immuno-oncology company focused on developing novel therapeutics to treat cancer. Unleash Immuno Oncolytics, is an immune-oncology company developing oncolytic virus immunotherapy products to treat cancer. Its lead product UIO-512, is an oncolytic virus designed to target malignant cells and tumor-associated stroma cells.
Unleash Immuno Oncolytics, Inc.
Unleashs lead product, UIO-512, is a conditionally replicative oncolytic adenovirus. UIO-512s viral replication is triggered by a triple hybrid promoter that combines the stroma-associated SPARC gene promoter and motifs responsive to tumor microenvironment conditions such as inflammation and hypoxia. UIO-512 is currently undergoing IND-enabling GMP manufacturing, pre-clinical, toxicology and biodistribution studies.
Unleash is also developing, UIO-702, a genetically-modified virus designed to target neoplastic metastatic disease.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/unleash-immuno-oncolytics” connections=”true” suffix=””]
In Feb 2016, Unleash Immuno signed a license agreement with INIS Biotech, the tech transfer arm of Leloir Institute and acquire further development rights of UIO- 512, an oncolytic virus that targets both malignant cells and tumor-associated stroma cells, thereby triggering an enhanced immune response.
In Feb 2018, Unleash Immuno raised $3 Mn Investment from Publicly-traded Japanese Company Oncolys BioPharma.